Ground-breaking Results from Treatment with CoQ10 Give New Hope for Heart Patients
Ground-breaking clinical trial results from treatment with CoQ10 give new hope for heart patients*. The CoQ10 treatment group shows 43% reduced complications and deaths as compared to the placebo group.
The results of the Q-Symbio study, a large international study of heart patients, have been published in the respected Journal of the American College of Cardiology (JACC). The study results were originally presented at a major cardiology congress in Lisbon, and Q-symbio ended up being the most frequently cited study of the congress.
Chief Physician Dr. Svend Aage Mortensen from Copenhagen University Hospital headed the study, which was carried out in hospitals in Denmark, Sweden, Poland, Austria, Hungary, Slovakia, Malaysia, Australia and India. Dr. Mortensen has said that he expects CoQ10 to become part of the future treatment for patients whose bodies lack adequate quantities of this natural substance. CoQ10 is a substance the body produces on its own, but the endogenous production declines with age.
According to Dr. Mortensen, the fact that JACC decided to publish the study is a breakthrough, as it is one of the most influential cardiology journals. Publication of the study results also shows that JACC has emphasized the exceptional results stemming from the CoQ10 treatment.
In some countries, Pharma Nord markets CoQ10 in the form of Myoqinon, a medical drug intended for the prevention and treatment of CoQ10 deficiency. Pharma Nord’s CoQ10 is also an OTC drug that is available from pharmacies and in health food stores; however, the majority of Pharma Nord’s CoQ10 is sold as a dietary supplement.
Professionals Choose Bio-Quinone CoQ10
Pharma Nord's medical drug, Myoqinon, was selected for the Q-Symbio study, partly because Pharma Nord’s CoQ10 is the official reference product of The International Coenzyme Q10 Association, but also because its effect has been documented in 75 human studies. The product has demonstrated good bioavailability and effect, and its production is based on safety data collected over a period of nearly 25 years. Pharma Nord’s CoQ10 is dissolved in oil and has undergone a special heat treatment that enables the CoQ10 crystals to dissolve completely at body temperature. This proprietary production process, which is used for all Pharma Nord's CoQ10 products (medical drugs as well as dietary supplements) produces a uniform (homogeneous) mixture unlike other products, which makes it easier for the body to absorb the CoQ10.
Ubiquinone: The Same Kind of CoQ10 that was used in the Study
CoQ10 exists in two active forms, the oxidized form (ubiquinone) and the reduced form (ubiquinol). Both forms are present in the mitochondria, the energy factories of the cells. Here, CoQ10 changes continuously between these two forms, oxidized and reduced, and this characteristic is essential for CoQ10's different responsibilities in the body.
Because, shortly efter ingestion, the body will convert ubiquinol, the reduced form of CoQ10, to oxidized CoQ10 (ubiquinone), you might as well purchase and use the oxidized form, the ubiquinone form which is much more cost-effective. To date, almost all scientific research on the efficacy and safety of CoQ10 has been conducted using the active, oxidized form, ubiquinone, which is the reason why Dr. Mortensen chose to use ubiquinone for the Q-Symbio study.
It is a misconception that either one of the CoQ10 forms, ubiquinone or ubiquinol, is superior or is a more active form than the other. In fact, both forms are important, as they perform different functions in the body. The form of CoQ10, which is produced in the liver, is the oxidized form of ubiquinone. CoQ10 from our food is a mix of the oxidized and the reduced form. Actually, CoQ10 is absorbed as ubiquinone and then is changed to the ubiquinol form in the lymph and enters the blood in the ubiquinol form.
*These statements has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.